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Abstract 
The serpin family of proteins consists primarily of proteinase inhibitors which form tight complexes with target proteinases. Inhibitor serpins are 
cleaved by proteinase and undergo a large conformational change in which the polypeptide segment erminating at the target reactive site, at which 
cleavage takes place, inserts itself as an additional strand, s4A, in the center of a preexisting/?-sheet. This change in conformation increases the stability 
towards denaturation of the cleaved serpin relative to the native uncleaved form. Mutant serpins with single amino acid changes in the s4A strand 
have been identified, and in most cases these are proteinase substrates but not inhibitors. We have measured the stability to denaturation of one of 
these non-inhibitor substrate mutants, antithrombin-Hamilton, which has an Ala + Thr change at position P12 in strand s4A. We find that it 
undergoes the transformation to the more stable form which is observed for inhibitor serpins, from which we conclude that the Ala + Thr change 
in antithrombin-Hamilton does not prevent insertion of s4A into B-sheet A in the cleaved form. 
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1. Introduction 
The serpins are a large family of proteins, most of 
which are inhibitors of serine proteinases [l-4]. They are 
distinct from the smaller proteinase inhibitors [5], such 
as basic pancreatic trypsin inhibitor, in being much 
larger and in having different mechanisms of inhibition. 
Both classes of inhibitors form tight complexes with tar- 
get proteinases, but covalent serpin-proteinase com- 
plexes are stable, even under denaturing conditions. The 
mechanism of serpin inhibition has a slow, irreversible 
step with the characteristics of suicide substrate inhibi- 
tion [6-91. It has been inferred from crystal structures of 
postcleavage serpins that the reactive site segment of 
serpins undergoes a large change in position upon cleav- 
age, from being exposed in the proteinase target site to 
being inserted as a new strand, s4A, in the preexisting 
p-sheet A [lO,l 11. This change is implicated in the inhib- 
itor activity of the serpins, since the non-inhibitor serpin, 
ovalbumin, does not undergo the strand insertion upon 
proteinase attack to form plakalbumin [ 12,131. This fail- 
ure to insert in plakalbumin has been attributed to the 
size and charge of residue Arg-345l in strand s4A, lo- 
cated at the P14 position with respect o the cleavage site 
at Pl. Insertion of s4A in plakalbumin into B-sheet A 
would require the insertion of the Arg-345 side chain into 
*Corresponding author. 
’ Sequence numbering and nomenclature of the secondary structural 
elements is that of Huber and Carrel1 [1 11. 
a hydrophobic interior pocket, which would be energeti- 
cally very unfavorable. This failure of s4A to insert into 
/?-sheet A in plakalbumin, and the fact that ovalbumin 
functions as a proteinase substrate instead of an inhibi- 
tor, led to the suggestion that strand insertion is a re- 
quirement for serpin inhibitor activity 1121. 
In addition to ovalbumin and plakalbumin, a number 
of serpin mutants at sites in strand s4A amino terminal 
to the cleavage site at Pl, have been identified [14-261. 
These point mutations occur primarily at positions PlO 
and P12, lack inhibitor activity, and usually but not al- 
ways, are cleaved as proteinase substrates. Their lack of 
inhibitor activity has been ascribed to the same failure 
of s4A to insert into b-sheet A that characterizes ovalbu- 
min: viz. altered size of an amino acid which must fit into 
the protein interior beneath /?-sheet A upon strand inser- 
tion. However, the link between inhibitory activity and 
this strand insertion is still not completely understood. 
Since these mutants offer a potential means of study- 
ing the relationship between strand insertion and pro- 
teinase inhibitor activity, we have determined whether 
cleavage of antithrombin-Hamilton by proteinase leads 
to the increase in stability to denaturation which is char- 
acteristic of insertion of s4A into B-sheet A in wild type 
serpins. We have measured the stability of intact an- 
tithrombin-Hamilton and its cleaved form and compared 
these with the stabilities of the corresponding wild type 
antithrombin. The results of these measurements are 
consistent with molecular model building studies which 
show that the P12 threonine of s4A can be accommo- 
dated in the strand inserted conformation of p-sheet A 
(Wright, H.T. and Scarsdale, J.N., submitted). 
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2. Materials and methods 
2.1. Isolation and purification of antithrombins 
Antithrombin was obtained from the propositus as a 50 : 50 mixture 
of wild type and antithrombin-Hamilton, and purified by heparin- 
Sepharose chromatography. Wild-type antithrombin was separated 
from cleaved antithrombin-Hamilton by thrombin-Sepharose chroma- 
tography [23]. The antithrombin mixture purified by heparin-Sepha- 
rose chromatography in 0.15 M NaCl, 0.02 M Tris, pH 7.5 (Tris- 
buffered saline, TBS) was suspended with an equal volume of throm- 
bin-Sepharose beads, washed with the same buffer, and incubated for 
60 min. The beads were then pelleted by brief centrifugation and the 
supernatant containing cleaved antithrombin-Hamilton removed. 
Measurements described here were made with the 50:50 mixture of 
uncleaved wild type antithrombin and antithrombin-Hamilton and 
with homogeneous cleaved antithrombin-Hamilton purified as de- 
scribed. 
Wild type antithrombin was purified by heparin-Sepharose chroma- 
tography and was homogeneous on SDS polyacrylamide gel. Cleaved 
wild type antithrombin was prepared by incubation with pancreatic 
elastase in TBS for 1 h under the conditions described by Olson [25]. 
Free heparin was removed by addition of a IO-fold excess (by weight) 
of protamine sulfate followed by centrifugation for 30 min at 16,000 x g 
in a microfuge. This sample was desalted on a Biogel P6DG column and 
concentrated by pressure dialysis. The sample was a single band and 
identified as cleaved by its slower mobility on a 9% non-reducing SDS 
PAGE gel. 
2.2. Denaturation profiles of antithrombins 
The stability to denaturation of the intact and cleaved forms of 
antithrombin was measured by monitoring the red shift of the intrinsic 
fluorescence as a function of guanidine hydrochloride concentration on 
a Shimadzu RFSOOOU spectrophotofluorometer [29]. Samples of an- 
tithrombin in TBS were diluted with water and with concentrated TBS 
and 8 M guanidine hydrochloride solution in water to give a final 
sample volume of 350 ~1 of 0.02 M Tris, 0.15 M NaCl, pH 7.5 at a 
concentration of 50 or 100 &ml of antithrombin in varying concentra- 
tions of guanidine hydrochloride. After equilibration at 25”C, samples 
were excited at a wavelength of 280 q and the I,,,, for emission 
determined from a scan between 300 w and 360 m,u. Data were 
expressed as a surrogate fractional concentration of native antithrom- 
bin in the expression: 
;1 
F= 
&natured - Ls 
a dcnatund - Live 
measured as a function of guanidine hydrochloride concentration. 
3. Results and discussion 
The denaturation curves for intact and cleaved an- 
tithrombin and antithrombin-Hamilton show that the 
cleaved forms of both the wild-type and mutant an- 
tithrombin are highly stabilized to denaturation relative 
to their intact forms (Fig. 1). This is consistent with 
insertion into B-sheet A of strand s4A, liberated from the 
reactive site region upon proteolysis, in the cleaved an- 
tithrombin-Hamilton mutant. 
Increased stability to denaturation of the inhibitor ser- 
pins, and lack of such stabilization in non-inhibitor ser- 
pins, following proteolytic cleavage has been observed a 
number of times [29-341 and has been ascribed to the 
insertion into /?-sheet A of the reactive site strand s4A 
liberated by peptide bond cleavage of the reactive site. 
The mutant serpins with single amino acid changes in 
this s4A strand in the PlO to P14 residues, by analogy 
to the case of ovalbumin/plakalbumin and angiotensino- 
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Fig. 1. Denaturation transition curves of antithrombin wild type and 
antithrombin-Hamilton measured as a function of guanidine hydro- 
chloride concentration. The parameter F, defined in the text, is the red 
shift of the emission maximum expressed as a fraction of the red shift 
for fully denatured antithrombin. (O = uncleaved wild type; l = un- 
cleaved mutant; G = cleaved wild type; L = cleaved mutant). 
gen [35], have been thought to be unable to insert s4A 
into /?-sheet A because of the substitution of an oversize 
or polar amino acid for the wild-type one [20]. This 
would be consistent with the observation from crystal 
structures that the even numbered residues (e.g. PlO, P12 
and P14), at which almost all the mutations are observed 
to occur, are oriented with their amino acid side chains 
facing inward to the hydrophobic interior of the mole- 
cule and are thus constrained in size and polarity if 
strand insertion is to occur. 
It has also been shown for cc,-proteinase inhibitor that 
uptake of exogenous free peptides of varying length, with 
sequences of the a,-proteinase inhibitor s4A strand, af- 
fect the inhibitor activity of the serpin [21]. Peptides of 
length and sequence corresponding to Pl-P12, Pl-P14, 
P8-P14 and P4P14 all abolish the inhibitor activity of 
a,-proteinase inhibitor and transform it into a trypsin 
substrate. Peptides truncated at the amino termal end 
corresponding to Pl-P8 up to Pl-Pl 1 retain significant 
inhibitor activity, but the amounts of stable complex 
formed with several proteinases relative to native inhibi- 
tor are reduced in the presence of these peptides. 
The observation described here of increased stability 
to denaturation of the antithrombin-Hamilton mutant is 
consistent with insertion of s4A into B-sheet A. This is 
further supported by model building studies of this mu- 
tant which indicate that the threonine residue can be 
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accommodated in the site occupied by alanine in the wild 
type (Wright, H.T. and Scarsdale, J.N., submitted). This 
model even suggests apossible increase in stability of the 
strand-inserted form of antithrombin-Hamilton relative 
to the wild type, based on the utilization of more hydro- 
gen bond donor and acceptor groups in buried positions 
under s4A, and we do observe a small increase in stabil- 
ity of cleaved antithrombin-Hamilton relative to the wild 
type (Fig. 1). 
The multiple serpin mutants in the PlO-P14 residues 
of s4A, and the structure of the non-inhibitor, ovalbu- 
min, are consistent with an important role for s4A inser- 
tion in serpin inhibitor activity. The peptide insertion 
studies of Schulze et al. [21] also imply that failure of the 
P12-P14 segment s4A to insert is sufficient to abolish 
inhibitor activity. However, the results on antithrombin- 
Hamilton reported here do not support the converse 
proposition that s4A insertion in P12-P14 is sufficient o 
confer inhibitor activity on a serpin. We suggest hat the 
kinetics of strand insertion may also play a role in deter- 
mining whether a serpin functions as an inhibitor. Inves- 
tigation of this possibility will require a different type of 
experiment than the equilibrium and static crystal studies 
done thus far. 
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